Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
1.990
-0.060 (-2.93%)
Jul 24, 2025, 4:00 PM - Market closed
Senti Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
34
Market Cap
51.88M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SNTI News
- 2 days ago - Senti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference - GlobeNewsWire
- 3 days ago - Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum - GlobeNewsWire
- 6 days ago - Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors - GlobeNewsWire
- 24 days ago - Senti Bio Participates in Nasdaq Amplify Spotlight Series - GlobeNewsWire
- 4 weeks ago - Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference - GlobeNewsWire
- 5 weeks ago - Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia - GlobeNewsWire
- 6 weeks ago - Senti Biosciences Announces New Employment Inducement Grants - GlobeNewsWire
- 6 weeks ago - Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC - GlobeNewsWire